Lantheus Holdings, Inc. $LNTH Stock Holdings Lifted by Carmignac Gestion

Carmignac Gestion increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 18.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,328,000 shares of the medical equipment provider’s stock after buying an additional 206,000 shares during the period. Lantheus comprises approximately 1.5% of Carmignac Gestion’s holdings, making the stock its 17th biggest position. Carmignac Gestion owned 2.04% of Lantheus worth $100,729,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Western Wealth Management LLC bought a new position in Lantheus in the first quarter worth about $25,000. Smartleaf Asset Management LLC boosted its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Parallel Advisors LLC grew its holdings in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Lantheus during the second quarter valued at approximately $36,000. Finally, Bessemer Group Inc. raised its position in shares of Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares during the period. Institutional investors own 99.06% of the company’s stock.

Get Lantheus alerts:

Lantheus Stock Performance

Shares of LNTH stock opened at $99.64 on Monday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The firm has a market capitalization of $6.49 billion, a price-to-earnings ratio of 24.01 and a beta of -0.03. The business has a 50 day simple moving average of $103.99 and a 200 day simple moving average of $86.87.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the business earned $1.53 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on LNTH shares. Truist Financial raised their price target on Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Brookline Capital Markets downgraded Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a report on Monday, June 29th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $109.71.

Check Out Our Latest Report on Lantheus

About Lantheus

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Read More

• Five stocks we like better than Lantheus
• 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
• AbbVie Quietly Solved Its Biggest Problem—Now What?
• Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
• Strategy’s Structural Strength: Hidden in a $8 Billion Illusion

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.